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Cholangiocarcinoma in Sclerosing Cholangitis. 
The Role of Liver Transplantation 
A. C. STIEBER, M.D., I. R. MARINO, M.D.: S. IWATSUKI, M.D., T. E. STARZL, M.D., 
Our experience with patients who underwent orthotopic liver 
transplantation for sclerosing cholangitis at the University of 
Pittsburgh Health Center between March 1980 and March 1988 
is reported here. Ten patients had an associated cholangiocarci-
noma. Six of these patients died of recurrent, disseminated 
cancer, usually before one year. One patient died of sepsis, 
while three are alive and apparently free of tumor four months 
to almost two years later. Pre-operative identification of a pos-
sible cholangiocarcinoma and complete resection are of crucial 
importance. Adjuvant therapy, especially pre-transplant radia-
tion with a prophylactic purpose is still being evaluated. 
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Recurrence. 
P rimary sclerosing cholangitis (PSC) is an unusual 
condition, characterized by a multiply segmental 
sclerosing and obliterative process involving the extra- or 
intrahepatic biliary tree, or frequently both. I Although 
found as a self-standing disease, it is commonly associated 
with inflammatory bowel disease (IBD) (mostly ulcera-
tive colitis, or rarely Crohn's disease); the percentage of 
sclerosing cholangitis patients with IBD has been variously 
reported to be between 30 and 70070, with an average of 
55%.2345 This disease affects men more frequently than 
women and it is diagnosed as a rule before the age of 50. 
The etiology is as yet unknown, though both an autoim-
mune component and a genotype predisposition seem to 
be suggested by the existing evidence. Immune complexes 
have been found in the serum of patients with sclerosing 
cholangitis, even in the absence of IBD,6 while radiola-
beled immune complexes have been found to be cleared 
more slowly from the serum of patients with PSC as 
opposed to normal controls. 7 Additionally, genetic studies 
have demonstrated what appears to be a predilection of 
HLA-B8 and HLA-Dr3 antigen types for development of 
PSC in the presence of IBD.8 
It presents with intermittent right upper quadrant pain, 
fluctuating jaundice, but with a general progressive trend, 
increasingly bothersome pruritus, nausea and vomiting 
and frequently recurrent episodes of cholangitis. Although 
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gallstones are not usually present, the gallbladder is gener-
ally abnormal, with the same inflammatory changes typi-
cal of PSC. The presence of gallstones, common duct 
stones or defects interpreted as evidence of choledocho-
lithiasis will often lead to exploratory laparotomy. Dur-
ing the procedure, the bile duct(s) will be found difficult 
to cannulate or explore and an intraoperative contrast 
study will demonstrate the characteristic lesions. In a great 
number of patients, the diagnosis of irreversible liver dis-
ease will be made at this point as well. 
The diagnosis is made by cholangiography (either retro-
grade or percutaneous transhepatic), which demonstrates 
the typical "beaded" bile ducts and is confirmed by bi-
opsy, which shows the inflammatory, sclerosing process 
involving the ducts and the periductal tissues. Charac-
teristically (but not exclusively), the alkaline phosphatase 
is elevated, while the other liver enzymes may be only mar-
ginally increased, if at all. Often, the first suspicion of 
biliary disease will be prompted by an incidental finding 
of elevated alkaline phosphatase. In advanced liver dis-
ease, the patients will have all the stigmata of end-stage 
secondary biliary cirrhosis, including ascites, esophageal 
varices, encephalopathy and hepatorenal syndrome. 
The traditional treatment, either medical (D-penicil-
lamine, 3 steroids, cholestyramine, azathioprine) or sur-
gical (by means of various exploratory methods with 
drainage) 9 10 has had very poor results; in one series, 113 
of the patients were dead within 57 months from diagno-
sis while another 113 had end-stage liver disease. 5 
During the last several years, orthotopic liver transplan-
tation (OLTX) has emerged as the therapeutical modality 
of choice for a majority of the patients with advanced 
PSC,lI The improved results with liver transplantation in 
general under a cyclosporine/prednisone regimen 12 as well 
as various technical refinements 13 14 have been responsi-
ble for making OLTX such a viable alternative. 
In this context, one observation made by our group has 
been the unusually high incidence of cholangiocarcinoma 
(CHC) in patients undergoing OLTX for PSC.9 While the 
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increased incidence of bile duct carcinoma in IBD had al-
ready been noted,l5 there had been no emphasis on the 
high incidence of CRC in association with SC to our 
knowledge. We report here the incidence, characteristics 
and results with OLTX for SC in the presence of CRC. 
Material and methods 
One-hundred and eleven patients underwent OL TX for PSC 
at the University of Pittsburgh Health Center between March 
1980 and March, 1988. Ten of the patients (9.1070) had CHC 
(Fig. 1). Three patients had known carcinoma at the time of 
transplantation. In the remaining seven patients, the carcinoma 
was an incidental finding during the pathological examination 
of the native hepatectomy specimen (Table I). 
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FIG. I.-Percentages of sclerosing cholangitis patients with and without 
cholangiocarcinoma. 
TABLE I.-List of all the patients with choiangiocarcinoma in this series. 
Name Age Sex Tumor Tx date Margin 
C.P. 33 F Known 05/13/1980 Free 
J.N. 47 F Known 10108/1985 Free 
G.M. 35 F Known 12/17/1985 Involved 
CHOLANGIOCARCINOMA IN SCLEROSING CHOLANGITIS 
All three patients with known tumor at the time of OL TX 
died of recurrence four to 17 months (mean 11 months) after 
transplantation. Three of the patients with incidental carcino-
ma died of disseminated recurrent carcinoma at 4.5, 12 and 14.5 
months respectively; all three had resection margin involved with 
tumor. A fourth patient died of sepsis 2.5 weeks after trans-
plantation. The remaining three are still alive and apparently free 
of tumor four months to almost two years after the transplant 
(Table I). 
Discussion 
As evidenced by our results, the prognosis of scleros-
ing cholangitis patients undergoing OL TX in the presence 
of cholangiocarcinoma is poor (Fig. 2). This is in agree-
ment with the results obtained with transplantation for 
primary bile duct carcinoma. 16 17 In our experience, none 
of the patients with known tumor at the time of trans-
plantation survived. Furthermore, half of the patients with 
incidental tumors died within a year. 
Interestingly enough, unlike non-transplant patients in 
whom cholangiocarcinoma is a very slowly progressing dis-
ease, that usually kills by obstructive sepsis, in our series 
the patients succumbed to very rapid and florid carcinoma-
tosis. This phenomenon is explained by the fact that the 
immunosuppressed transplant patient cannot mount any 
effective anti-tumoral defence. 
Post-operative treatment with radiation and/or chemo-
therapy has so far been clearly ineffective in preventive 
recurrence. On the other hand, the patients with inciden-
tal carcinoma and resection margins free of tumor seem 
to have a much better prognosis, though the numbers are 
still very small and the follow-up limited. 
Based on these results, we believe that every effort must 
be made in order to diagnose the presence of cholangio-
carcinoma pretransplant and, if the tumor is found, to 
try to document its extension. Repeated brush biopsies 
during pretransplant percutaneous transhepatic cholangio-
gram (PTC) or endoscopic retrograde choledochopan-
Recurrence Site(s) Status Interval (*) 
Yes Bile duct, liver, jejunum Dead 12 months 
Yes Liver, bones, lungs Dead 17 months 
Yes Carcinomatosis Dead 4 months 
Lymph nodes 
Small bowel 
M.M. 24 M Incidental 06/07/1986 Free No NA Alive 24 months 
P.R. 37 M Incidental 06/09/1986 Free No NA Alive 24 months 
B.D. 58 M Incidental 06/19/1986 Free Yes Bile duct, liver, bones Dead 13 months 
G.B. 61 M Incidental 08/30/1986 Free Yes Bones, liver, peritoneum Dead 15 months 
09/03/1986 
B.S. 61 M Incidental 1211811986 Free No Died of sepsis on POD 6 Dead < 1 month 
Liver transplant 
Kidney transplant 
S.R. 56 M Incidental 12112/1986 Involved Yes Liver, bones Dead 5 months 
J.L. 42 M Incidental 01122/1988 Free No NA Alive 6 months 
(gallbladder) 
(*) In months to death or follow-up length. 
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FIG. 2.-Survival of patients with cholangiocarcinoma (dotted/dash 
line) versus that of patients without cancer (solid line). 
creatogram (ERCP) must be obtained in every patient 
who is being considered for liver transplantation candi-
dacy. If a tumor is found, an attempt to evaluate the 
extension, via PTC or even pretransplant exploratory 
laparotomy with biopsy should be seriously considered, 
since only complete resection of the tumor may offer a 
chance of survival. Pretransplant radiation therapy (either 
by external beam or internal implantation) may playa role 
in allowing the resection of the tumor-involved liver and 
in the improvement of survival, but this approach is only 
now being evaluated and several more years will be need-
ed before any firm conclusion can be drawn. Last but not 
least, as there seems to be a direct correlation between the 
duration of PSC and the higher incidence of cholangiocar-
cinoma, it may be justified to recommend liver transplan-
tation. at an earlier time than otherwise indicated by the 
patient's general condition. 
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